Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes

Drug Metab Dispos. 2004 Apr;32(4):447-54. doi: 10.1124/dmd.32.4.447.

Abstract

Oxycodone undergoes N-demethylation to noroxycodone and O-demethylation to oxymorphone. The cytochrome P450 (P450) isoforms capable of mediating the oxidation of oxycodone to oxymorphone and noroxycodone were identified using a panel of recombinant human P450s. CYP3A4 and CYP3A5 displayed the highest activity for oxycodone N-demethylation; intrinsic clearance for CYP3A5 was slightly higher than that for CYP3A4. CYP2D6 had the highest activity for O-demethylation. Multienzyme, Michaelis-Menten kinetics were observed for both oxidative reactions in microsomes prepared from five human livers. Inhibition with ketoconazole showed that CYP3A is the high affinity enzyme for oxycodone N-demethylation; ketoconazole inhibited >90% of noroxycodone formation at low substrate concentrations. CYP3A-mediated noroxycodone formation exhibited a mean K(m) of 600 +/- 119 microM and a V(max) that ranged from 716 to 14523 pmol/mg/min. Contribution from the low affinity enzyme(s) did not exceed 8% of total intrinsic clearance for N-demethylation. Quinidine inhibition showed that CYP2D6 is the high affinity enzyme for O-demethylation with a mean K(m) of 130 +/- 33 microM and a V(max) that ranged from 89 to 356 pmol/mg/min. Activity of the low affinity enzyme(s) accounted for 10 to 26% of total intrinsic clearance for O-demethylation. On average, the total intrinsic clearance for noroxycodone formation was 8 times greater than that for oxymorphone formation across the five liver microsomal preparations (10.5 microl/min/mg versus 1.5 microl/min/mg). Experiments with human intestinal mucosal microsomes indicated lower N-demethylation activity (20-50%) compared with liver microsomes and negligible O-demethylation activity, which predict a minimal contribution of intestinal mucosa in the first-pass oxidative metabolism of oxycodone.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aryl Hydrocarbon Hydroxylases / genetics
  • Aryl Hydrocarbon Hydroxylases / metabolism*
  • Aryl Hydrocarbon Hydroxylases / pharmacology
  • Biotransformation
  • Cytochrome P-450 CYP2D6 / genetics
  • Cytochrome P-450 CYP2D6 / metabolism*
  • Cytochrome P-450 CYP2D6 / pharmacology
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme System / genetics
  • Cytochrome P-450 Enzyme System / metabolism
  • DNA, Complementary / genetics
  • Humans
  • Intestinal Mucosa / metabolism
  • Intestines / drug effects
  • Intestines / ultrastructure*
  • Ketoconazole / metabolism
  • Ketoconazole / pharmacology
  • Kinetics
  • Metabolic Clearance Rate
  • Methylation / drug effects
  • Microsomes / drug effects
  • Microsomes / metabolism
  • Microsomes, Liver / chemistry
  • Microsomes, Liver / drug effects
  • Microsomes, Liver / metabolism*
  • Molecular Structure
  • Morphinans / antagonists & inhibitors
  • Morphinans / chemistry
  • Morphinans / metabolism
  • Oxidoreductases, N-Demethylating / genetics
  • Oxidoreductases, N-Demethylating / metabolism*
  • Oxidoreductases, N-Demethylating / pharmacology
  • Oxycodone / metabolism*
  • Oxycodone / pharmacology
  • Oxymorphone / chemistry
  • Oxymorphone / metabolism
  • Protein Binding / drug effects
  • Quinidine / adverse effects
  • Quinidine / antagonists & inhibitors
  • Quinidine / pharmacology

Substances

  • DNA, Complementary
  • Morphinans
  • Cytochrome P-450 Enzyme System
  • noroxycodone
  • Oxymorphone
  • Oxycodone
  • Aryl Hydrocarbon Hydroxylases
  • CYP3A protein, human
  • CYP3A5 protein, human
  • Cytochrome P-450 CYP2D6
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human
  • Oxidoreductases, N-Demethylating
  • Quinidine
  • Ketoconazole